journal
MENU ▼
Read by QxMD icon Read
search

Oncology

journal
https://www.readbyqxmd.com/read/28633143/tumor-associated-macrophages-in-the-development-of-4-nitroquinoline-1-oxide-induced-tongue-squamous-cell-carcinoma-in-a-mouse-model
#1
Kentaro Miki, Yorihisa Orita, Yuka Gion, Soshi Takao, Kyotaro Ohno, Mai Takeuchi, Toshihiro Ito, Akira Minoura, Tomoyasu Tachibana, Hidenori Marunaka, Takuma Makino, Akihiro Matsukawa, Kazunori Nishizaki, Tadashi Yoshino, Yasuharu Sato
OBJECTIVE: We aimed to determine the distribution of tumor-associated macrophages (TAMs) in the development of tongue squamous cell carcinoma (SCC) and to elucidate the role of TAMs in the progression of tongue SCC. METHODS: The expression of the macrophage markers nitric oxide synthase, Retnla, and mannose receptor 1 in the development of tongue SCC was longitudinally observed using real-time quantitative polymerase chain reaction. Additionally, an immunohistochemical study using an anti-mannose receptor (MR) antibody was performed...
June 21, 2017: Oncology
https://www.readbyqxmd.com/read/28614816/optimizing-quality-of-life-in-patients-with-hormone-receptor-positive-metastatic-breast-cancer-treatment-options-and-considerations
#2
Pavani Chalasani
The treatment landscape for hormone receptor-positive metastatic breast cancer continues to evolve as the molecular mechanisms of this heterogeneous disease are better understood and targeted treatment strategies are developed. Patients are now living for extended periods of time with this disease as they progress through sequential lines of treatment. With a rapidly expanding therapeutic armamentarium, the prevalence of metastatic breast cancer patients with prolonged survival is expected to increase, as is the duration of survival...
June 15, 2017: Oncology
https://www.readbyqxmd.com/read/28609768/financial-implication-of-radioactive-iodine-therapy-for-early-stage-papillary-thyroid-cancer
#3
Zaid Al-Qurayshi, Daniah Bu Ali, Sudesh Srivastav, Emad Kandil
OBJECTIVE: The aim of this study was to evaluate disease-specific survival and cost related to radioactive iodine therapy (RAI) utilization in patients with early-stage papillary thyroid carcinoma (PTC). METHODS: This was a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database, 2004-2012. RESULTS: A total of 38,374 patients with PTC were identified. Of those, 56.3% had adjuvant RAI. RAI administration was not associated with a survival advantage in patients with PTC stage I (hazard ratio [HR] 1...
June 14, 2017: Oncology
https://www.readbyqxmd.com/read/28601879/outcomes-in-melanoma-patients-treated-with-braf-mek-directed-therapy-or-immune-checkpoint-inhibition-stratified-by-clinical-trial-versus-standard-of-care
#4
Chloe Goldman, Jeremy Tchack, Eric M Robinson, Sung Won Han, Una Moran, David Polsky, Russell S Berman, Richard L Shapiro, Patrick A Ott, Iman Osman, Hua Zhong, Anna C Pavlick, Melissa Ann Wilson
OBJECTIVES: Since 2011, metastatic melanoma treatment has evolved with commercial approval of BRAF- and MEK-targeted therapy and CTLA-4- and PD-1-blocking antibodies (immune checkpoint inhibitors, ICI). While novel therapies have demonstrated improved prognosis in clinical trials, few studies have examined the evolution of prognosis and toxicity of these drugs among an unselected population. We assess whether survival and toxicity reported in trials, which typically exclude most patients with brain metastases and poor performance status, are recapitulated within a commercial access population...
June 10, 2017: Oncology
https://www.readbyqxmd.com/read/28571030/less-fibrotic-burden-differently-affects-the-long-term-outcomes-of-hepatocellular-carcinoma-after-curative-resection
#5
Hye Won Lee, Gi Hong Choi, Do Young Kim, Young Nyun Park, Kyung Sik Kim, Jin Sub Choi, Sang Hoon Ahn, Kwang-Hyub Han
BACKGROUND: The clinical features of hepatocellular carcinoma (HCC) differ in patients with and without cirrhosis. OBJECTIVE: We aimed to investigate the long-term outcomes of noncirrhotic HCC patients after curative resection. METHODS: We retrospectively examined 649 consecutive patients with HCC who underwent curative resection from 1996 to 2012; 387 (59.6%) were cirrhotic and 262 (40.4%) were noncirrhotic. RESULTS: The mean age was 54...
June 2, 2017: Oncology
https://www.readbyqxmd.com/read/28571009/surgery-is-an-effective-option-after-failure-of-chemoradiation-in-cancers-of-the-anal-canal-and-anal-margin
#6
Jean-Baptiste Delhorme, François Severac, Waisse Waissi, Benoit Romain, Delphine Antoni, Kelle C Freel, Catherine Schumacher, Serge Rohr, Cécile Brigand, Georges Noël
BACKGROUND: Surgery for anal canal cancer (ACC) and anal margin cancer (AMC) is the only curative option after failure of chemoradiotherapy (CRT). This study aimed to determine the efficacy of surgery for ACC or AMC after failed CRT. METHODS: This was a single-centre, retrospective study of 161 patients initially treated with CRT. We compared the survival rates of patients successfully treated by CRT with those of patients whose CRT failed (both surgically salvaged and treated palliatively)...
June 2, 2017: Oncology
https://www.readbyqxmd.com/read/28558382/znf750-expression-as-a-novel-candidate-biomarker-of-chemoradiosensitivity-in-esophageal-squamous-cell-carcinoma
#7
Ryota Otsuka, Yasunori Akutsu, Haruhito Sakata, Naoyuki Hanari, Kentaro Murakami, Masayuki Kano, Masahiko Takahashi, Yasunori Matsumoto, Nobufumi Sekino, Masaya Yokoyama, Keiko Iida, Hisahiro Matsubara
OBJECTIVE: ZNF750, an epidermal differentiation regulator, has been suggested to act as a tumor suppressor of esophageal squamous cell carcinoma (ESCC). Although a correlation between the epidermal differentiation gene and resistance to chemoradiotherapy (CRT) has been posited, no data regarding the ZNF750 status in ESCC have been reported. The aim of the present study was to evaluate the relationship between ZNF750 expression and response to CRT in ESCC. METHODS: Eighty-seven patients who had been pathologically diagnosed with ESCC were evaluated in the present study...
May 31, 2017: Oncology
https://www.readbyqxmd.com/read/28531891/dual-inhibition-of-egfr-and-vegf-in-heavily-pretreated-patients-with-metastatic-colorectal-cancer
#8
Finn Ole Larsen, Alice Markussen, Dorte Nielsen, Bonnie Colville-Ebeling, Lene B Riis, Benny V Jensen
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic colorectal cancer. METHODS: All patients had KRAS wild-type metastatic colorectal cancer and had previously received fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab/panitumumab in a 1st, 2nd, and 3rd line setting. Most patients had previously received bevacizumab as well...
May 23, 2017: Oncology
https://www.readbyqxmd.com/read/28521313/amrubicin-monotherapy-for-patients-with-platinum-pretreated-non-gastrointestinal-non-pancreatic-extrapulmonary-neuroendocrine-carcinoma
#9
Takahiro Ebata, Tatsunori Shimoi, Tsukasa Ishiwata, Shunichiro Iwasawa, Seiko Bun, Mayu Yunokawa, Kan Yonemori, Yuichi Takiguchi, Kenji Tamura
OBJECTIVE: The aim of this study was to investigate the clinical usefulness of amrubicin therapy for patients with non-gastrointestinal (GI) non-pancreatic extrapulmonary neuroendocrine carcinoma (EP-NEC). METHODS: The medical records of patients from the 2 participating institutions were retrospectively reviewed. The eligibility criteria were: patients with non-GI non-pancreatic EP-NEC who received amrubicin monotherapy after platinum-based chemotherapy. Patients in whom the platinum-free interval (interval between the last day of platinum administration and the first subsequent documentation of disease progression) was 90 days or longer were classified into the platinum-sensitive group...
May 19, 2017: Oncology
https://www.readbyqxmd.com/read/28511189/the-role-of-audiometry-prior-to-high-dose-cisplatin-in-patients-with-head-and-neck-cancer
#10
Miguel Caballero, Paula Mackers, Oscar Reig, Elvira Buxo, Pilar Navarrete, Jose L Blanch, Juan J Grau
OBJECTIVES: To analyze the role of audiometry in considering change to a less ototoxic treatment in head and neck cancer (HNC) patients. METHODS: Consecutive patients prescribed high-dose cisplatin (100 mg/m2) between January 2013 and February 2015 were enrolled. Audiometry was performed at baseline and before cisplatin. Change to a less ototoxic agent or reduced cisplatin dose was considered with audiometric decreases >25 dB. RESULTS: A total of 103 patients were included; the median age of the patients was 59 years (range 18-75)...
May 17, 2017: Oncology
https://www.readbyqxmd.com/read/28511180/response-predictors-of-s-1-cisplatin-and-docetaxel-combination-chemotherapy-for-metastatic-gastric-cancer-microarray-analysis-of-whole-human-genes
#11
Shinji Kitamura, Toshihito Tanahashi, Eriko Aoyagi, Tadahiko Nakagawa, Koichi Okamoto, Tetsuo Kimura, Hiroshi Miyamoto, Yasuhiro Mitsui, Kazuhito Rokutan, Naoki Muguruma, Tetsuji Takayama
OBJECTIVES: The aim of this study was to identify biomarkers for predicting the efficacy of docetaxel, cisplatin, and S-1 (DCS) therapy for advanced gastric cancer using microarrays of biopsy specimens before chemotherapy. METHODS: Nineteen samples were taken from 19 patients with unresectable metastatic gastric cancer who received DCS as a first-line therapy. Laser capture microdissection was performed, and total cellular RNA was extracted from each microdissected sample...
May 17, 2017: Oncology
https://www.readbyqxmd.com/read/28486226/role-of-albumin-in-growth-inhibition-in-hepatocellular-carcinoma
#12
Ezgi Bağırsakçı, Eren Şahin, Neşe Atabey, Esra Erdal, Vito Guerra, Brian I Carr
OBJECTIVE: Levels of serum albumin have recently emerged, together with C-reactive protein, as an important prognostic indicator for hepatocellular carcinoma (HCC). It has recently been reported that larger HCCs are associated with lower albumin levels. However, the albumin-mediated growth decrease has yet to be determined. METHODS: We examined a large HCC cohort and then by direct exposure of HCC cells in vitro, the relationship of albumin levels to HCC growth...
May 10, 2017: Oncology
https://www.readbyqxmd.com/read/28478451/role-of-her2-related-biomarkers-her2-p95her2-her3-pten-and-pik3ca-in-the-efficacy-of-lapatinib-plus-capecitabine-in-her2-positive-advanced-breast-cancer-refractory-to-trastuzumab
#13
Reiki Nishimura, Uhi Toh, Maki Tanaka, Michiyo Saimura, Yasuhiro Okumura, Tsuyoshi Saito, Toshihiro Tanaka, Megumi Teraoka, Kazuo Shimada, Kazuhisa Katayama, Toshihiro Koga, Kaname Kurashita, Satoshi Hasegawa, Hidekazu Todoroki, Yuichiro Kai, Yasuyo Ohi, Satoshi Toyoshima, Nobuyuki Arima, Shoshu Mitsuyama, Kazuo Tamura
OBJECTIVE: The aim of this study was to investigate the correlation between human epidermal growth factor receptor 2 (HER2)-related biomarkers and the treatment outcomes using lapatinib plus capecitabine (LC) and to evaluate the influence of the estrogen receptor (ER) status in trastuzumab-refractory HER2-positive advanced breast cancer. METHOD: Eighty patients were enrolled in this study. Total HER2, p95HER2, and total HER3 expression were quantified using the VeraTag assays...
May 6, 2017: Oncology
https://www.readbyqxmd.com/read/28472802/evaluation-of-the-effectiveness-of-a-multimodal-complementary-medicine-program-for-improving-the-quality-of-life-of-cancer-patients-during-adjuvant-radiotherapy-and-or-chemotherapy-or-outpatient-aftercare
#14
Martin Domnick, Manju Domnick, Karl-Rüdiger Wiebelitz, André-Michael Beer
OBJECTIVES: Evidence for complementary therapies as important strategies to relieve cancer treatment-associated symptoms is increasing. Mostly, these complementary therapies start at the end of adjuvant treatments, resulting in a long delay until the well-being of patients is addressed. Further, long distances between the rehabilitation center and the patients' residence hinder patients' compliance. METHODS: The multimodal outpatient LOTUS Care Cure Project (LCCP) was tested in a randomized controlled trial including patients of various cancer entities and stages while on adjuvant chemotherapy and/or radiotherapy or outpatient aftercare...
May 5, 2017: Oncology
https://www.readbyqxmd.com/read/28463843/prognostic-parameters-for-patients-with-cervical-cancer-figo-stages-ia2-iib-a-long-term-follow-up
#15
Bogdan Obrzut, Andrzej Semczuk, Maciej Naróg, Marzanna Obrzut, Piotr Król
OBJECTIVE: We assessed the prognostic factors related to 10-year overall survival and disease-free survival in cervical cancer patients that underwent primary surgical protocols in 1 institution. MATERIALS AND METHODS: A total of 102 patients with uterine cervical cancer at FIGO stages IA2-IIB that underwent a Piver type III radical hysterectomy and pelvic lymphadenectomy between 1998 and 2001 were included. Univariate and multivariate analyses of 10-year overall survival and 10-year disease-free survival were performed...
May 3, 2017: Oncology
https://www.readbyqxmd.com/read/28463827/taurolidine-citrate-lock-therapy-for-primary-prevention-of-catheter-related-infections-in-cancer-patients-results-of-a-prospective-randomized-phase-iv-trial-atapac
#16
Raffaele Longo, Mathieu Llorens, Christophe Goetz, Christian Platini, Nada Eid, Jocelyne Sellies, Nadia Ouamara, Philippe Quétin
BACKGROUND: Totally implantable venous access port (TIVAP)-related infections (RIs) remain a serious health problem in cancer patients receiving an intravenous (i.v.) therapy. PATIENTS AND METHODS: The ATAPAC study was a prospective, randomized, monocentric, phase IV trial evaluating the efficacy of taurolidine lock solution versus standard saline solution for primary TIVAP-RI prevention in nonhematological cancer patients receiving i.v. chemotherapy. The primary endpoint was the TIVAP-RI incidence rate...
May 3, 2017: Oncology
https://www.readbyqxmd.com/read/28448999/outcome-of-all-oral-direct-acting-antiviral-regimens-on-the-rate-of-development-of-hepatocellular-carcinoma-in-patients-with-hepatitis-c-virus-genotype-1-related-chronic-liver-disease
#17
Fumihiro Ogata, Masahiro Kobayashi, Norio Akuta, Mitutaka Osawa, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Mariko Kobayashi, Satoshi Saitoh, Yoshiyuki Suzuki, Fumitaka Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
OBJECTIVES: There is little information on the risk factors for hepatocellular carcinoma (HCC) and outcome of treatment with an all-oral combination of direct-acting antiviral regimens following eradication of hepatitis C virus (HCV) RNA. METHODS: The study subjects were 1,170 patients with HCV genotype 1-related chronic liver disease treated with either NS5A inhibitor plus NS3/4A protease inhibitor (n = 707), NS5A inhibitor plus NS5B polymerase inhibitor (n = 345), or NS5A inhibitor, NS3/4A protease inhibitor plus ritonavir (n = 118), for 12-24 weeks...
April 28, 2017: Oncology
https://www.readbyqxmd.com/read/28448997/altered-expression-of-hippo-signaling-pathway-molecules-in-intrahepatic-cholangiocarcinoma
#18
Keishi Sugimachi, Miki Nishio, Shinichi Aishima, Yosuke Kuroda, Tomohiro Iguchi, Hisateru Komatsu, Hidenari Hirata, Shotaro Sakimura, Hidetoshi Eguchi, Yuki Bekki, Kenji Takenaka, Yoshihiko Maehara, Akira Suzuki, Koshi Mimori
OBJECTIVE: MOB1, a core component of the Hippo signaling pathway, suppresses cell proliferation, and MOB1 liver conditional knockout mice develop intrahepatic cholangiocarcinoma (ICC). However, its clinical significance in human ICC has not been established. The aim of this study was to characterize protein levels and the role of Hippo and TGF pathways in ICCs. METHODS: The protein levels of yes-associated protein 1 (YAP1), MOB1, Smad2, and TGFβ2 in 88 ICC cases were analyzed...
April 28, 2017: Oncology
https://www.readbyqxmd.com/read/28445892/feasibility-of-modified-folfox-in-elderly-patients-aged-%C3%A2-80-years-with-metastatic-gastric-cancer-or-colorectal-cancer
#19
Kyu-Hyoung Lim, Hui-Young Lee, Sung Bae Park, Seo-Young Song
OBJECTIVE: The aim of this study was to assess the feasibility of a modified FOLFOX regimen as first-line treatment in elderly patients with metastatic gastric cancer (GC) or colorectal cancer (CRC). METHODS: We included chemotherapy-naïve patients over 80 years old with metastatic GC or CRC in our study. From September 2008 to November 2014, 28 consecutive patients were enrolled and treated with modified FOLFOX. RESULTS: The study population consisted of an equal number of GC and CRC patients...
April 27, 2017: Oncology
https://www.readbyqxmd.com/read/28423384/cetuximab-carboplatin-5-fluorouracil-regimen-in-elderly-patients-with-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-a-french-retrospective-survey
#20
Mickaël Burgy, Philippe Barthélémy, François Lefevre, Agnès Dupret-Bories, Pierre Truntzer, Clement Korenbaum, Henri Flesch, Guy Bronner, Christian Borel
BACKGROUND: The cetuximab plus platinum-based chemotherapy regimen is a standard of care in the treatment of recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). The feasibility in the elderly population is currently unknown. METHODS: We performed a retrospective study in order to assess the efficacy and safety of the cetuximab plus platinum-based chemotherapy regimen in patients >65 years with recurrent or metastatic HNSCC. We performed a retrospective review of all medical records from recurrent or metastatic HNSCC patients >65 years treated with the cetuximab plus platinum-based chemotherapy regimen between September 2008 and December 2013 in our institution (Centre Paul Strauss, Strasbourg, France)...
April 20, 2017: Oncology
journal
journal
21814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"